Antiarrhythmics : elimination and dosage considerations in hepatic impairment.

Antiarrhythmics : elimination and dosage considerations in hepatic impairment. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Antiarrhythmics : elimination and dosage considerations in hepatic impairment. Abstract Text:

Ulrich Klotz,Ulrich Klotz,Ulrich Klotz,

Many drugs, including most antiarrhythmics (some of which are now of limited clinical use) are eliminated by the hepatic route. If liver function is impaired, it can be anticipated that hepatic clearance will be delayed, which can lead to more pronounced drug accumulation with multiple dosing. Consequently, the potential risks of adverse events could be increased, especially as antiarrhythmics have a narrow therapeutic index.The present review summarises the available pharmacokinetic data on the most popular antiarrhythmic drugs to identify the enzymes involved in the metabolism of the various agents and confirm whether liver disease affects their elimination. Despite long usage of some of these drugs (e.g. amiodarone, diltiazem, disopyramide, procainamide and quinidine), surprisingly few data are available in patients with liver disease, making it difficult to give recommendations for dosage adjustment. In contrast, for carvedilol, lidocaine (lignocaine), propafenone and verapamil, sufficient clinical studies have been performed. For these drugs, a marked decrease in systemic and/or oral clearance and significant prolongation of the elimination half-life have been documented, which should be counteracted by a 2- to 3-fold reduction of the dosage in patients with moderate to severe liver cirrhosis. For sotalol, disopyramide and procainamide, renal clearance contributes considerably to overall elimination, suggesting that dosage reductions are probably unnecessary in patients with liver disease as long as renal function is normal.The hepatically eliminated antiarrhythmics are metabolised mainly by different cytochrome P450 (CYP) isoenzymes (e.g. CYP3A4, CYP1A2, CYP2C9, CYP2D6) and partly also by conjugations. As the extent of impairment in clearance is in the same range for all of these agents, it could be assumed that they have a common vulnerability and that, consequently, hepatic dysfunction will affect CYP-mediated phase I pathways in a similar fashion. The severity of liver disease has been estimated clinically by the validated Pugh score, and functionally by calculation of the clearance of probe drugs (e.g. antipyrine). Both approaches can be helpful in estimating/predicting impairments in drug metabolism, including antiarrhythmics.In conclusion, hepatic impairment decreases the elimination of many antiarrhythmics to such an extent that dosage reductions are highly recommended in such populations, especially in patients with cirrhosis.

Antiarrhythmics : elimination and dosage considerations in hepatic impairment. Publishing Authors By Initials

U Klotz,U Klotz,U Klotz,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Antiarrhythmics : elimination and dosage considerations in hepatic impairment. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical pharmacokinetics

VOLUME: 46

Page Numbers: 985-96

Journal Abbreviation:

ISSN: 0312-5963

DAY: 21

MONTH: 11

YEAR: 2007

Antiarrhythmics : elimination and dosage considerations in hepatic impairment. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7606849

Antiarrhythmics : elimination and dosage considerations in hepatic impairment. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Antiarrhythmics : elimination and dosage considerations in hepatic impairment. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Antiarrhythmics : elimination and dosage considerations in hepatic impairment.

AFFILIATION: Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, GermanyUniversity of Tübingen, Tübingen, Germany.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Pharmacokinet

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Antiarrhythmics : elimination and dosage considerations in hepatic impairment Related Publications

• Active surveillance for favorable risk prostate cancer: Rationale, risks, and results.
• Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it?
• Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?
• An Sfi1p-Like Centrin-Binding Protein Mediates Centrin-Based Ca2+-Dependent Contractility in Paramecium tetraurelia.
• Antiarrhythmics : elimination and dosage considerations in hepatic impairment.
• Casting a wider net for countermeasure r&d funding decisions.
• Characterization of Two New Genes, amoR and amoD, in the amo Operon of the Marine Ammonia Oxidizer Nitrosococcus oceani ATCC 19707.
• Drug-related risks.
• Epidermal growth factor- and stress-induced loss of gap junctional communication is mediated by ERK-1/ERK-2 but not ERK-5 in rat liver epithelial cells.
• How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?
• Nomadic or sessile: can Kupffer cells function as portals for malaria sporozoites to the liver?
• North American blastomycosis (Gilchrist's disease) a study of the disease from a review of the literature.
• North American blastomycosis (Gilchrist's disease) an analysis of Canadian reports and description of a new case of the systemic type.
• Pencil penetrates orbit.
• Some aspects of the action of sulfonamides; rate-controlling processes in growth studies with Escherichia coli.
• Stimulation of selenoprotein P promoter activity in hepatoma cells by FoxO1a transcription factor.
• The bridging function of clinical pharmacology.
• The impact of genome analyses on our understanding of ammonia-oxidizing bacteria.
• Thorn in body causing abscess after 21 years.
• Transport studies with 5-aminosalicylate.
• Unchanged serum levels of advanced glycation endproducts in patients with liver disease.
• [Healthy lifestyles and help-seeking in males - no improvement in sight.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]